tickerreport.com
Positivewww.tickerreport.com ·
Abcellera Biologics Nasdaqabcl Lowered to Sell Rating by Wall Street Zen
AnalystNutritional ProgramsFood And In Kind TransfersTherapeutic
Topic context
This topic has been covered 366199 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedSingle-company analyst downgrade for AbCellera Biologics, a biotech firm. No direct commodity, supply chain, or sector-wide commercial mechanism. Impact is limited to the company's stock valuation and investor sentiment. No scarcity or margin channel identified.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- AbCellera Biologics (NASDAQ: ABCL) downgraded from hold to sell by Wall Street Zen on May 17, 2026.
- Stock opened at $4.09, market cap $1.25 billion.
- Reported EPS ($0.14) vs estimate ($0.22), revenue $8.32 million.
- Consensus rating 'Moderate Buy' with average target $7.80.
Related stories
finance.yahoo.com
Ncmi Q1 2026 Earnings Transcript
finance.yahoo.com
Transcript Valneva Q1 2026 Earnings
finance.yahoo.com
Aytu Aytu Q3 2026 Earnings
fool.com
Keysight Keys Q2 2026 Earnings Transcript
livemint.com